在生物治疗期间和之后,牛皮患者的恶性瘤:单中心体验
Hiroyuki Sakai1, Masako Minami-Hori1, Shiro Kuwahara1
1Division of Dermatology, Asahikawa City Hospital, Asahikawa, Japan.
The Journal of dermatology
|November 16, 2024
概括
用生物药物治疗的牛皮患者患恶性瘤的发病率较高,包括泌尿器官,血液和胃肠道癌症. 通过Krebs von den Lungen-6等生物标志物的早期检测对于管理这些风险至关重要.
科学领域:
- 皮肤病学 皮肤病学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 牛皮是一种慢性炎症性疾病.
- 生物制剂是适度至重症牛皮的有效治疗方法.
- 有关生物制剂的长期安全性,特别是癌症风险存在担忧.
研究的目的:
- 为了研究用生物药物治疗的牛皮病患者恶性瘤的发生率.
- 在这个人群中确定与生物疗法相关的特定类型的癌症.
- 提高皮肤科医生对潜在的癌症风险的认识.
主要方法:
- 从2010年到2023年用生物药物治疗的86名牛皮患者的回顾性分析.
- 在治疗期间诊断的所有恶性瘤的文件.
- 对患者数据的审查,包括特定器官的癌症类型和诊断标记.
主要成果:
- 在14年内,86名患者中有11名患有12种恶性瘤.
- 癌症类型包括:4种泌尿器官癌症,3种血液癌症,2种胃肠癌,1种乳腺癌,1种甲状腺癌,1种肺癌.
- 升高的Krebs von den Lungen-6水平有助于在无症状患者中检测肝内胆管癌和甲状腺癌.
结论:
- 接受生物治疗的牛皮患者患有恶性瘤的风险增加.
- 皮肤科医生必须对接受生物治疗的患者潜在的癌症发展保持警.
- 诸如Krebs von den Lungen-6等生物标志物可能有助于早期发现癌症,即使没有症状.
相关概念视频
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Skin Cancer
3.8K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.8K
T Cell Types and Functions
954
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
954
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


